TP53 and acute myeloid leukemia: In AML with wild-type TP53, the p53 tumour suppressor protein is commonly held functionally inert through dysregulation of the ARF-MDM2/4 axis, culminating in inactivation of p53 by its negative regulators, MDM2 and MDM45.